{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-362806","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2021-12-21T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.364999+00:00","generated_at":"2026-06-27T23:10:40.015245+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acadia plans Q1 2022 sNDA resubmission for pimavanserin in Alzheimer's disease psychosis","bullets":["Resubmission targets Alzheimer's disease psychosis (ADP) instead of broader dementia-related psychosis.","sNDA includes data from two positive Phase 3 studies: HARMONY and -019, meeting primary endpoints.","New analyses address FDA complete response letter concerns; plan follows three meetings with FDA.","CEO Steve Davis says narrowed indication and additional data support case for first ADP drug approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-362806","json":"https://secwatch.observer/filing/0001193125-21-362806.json","markdown":"https://secwatch.observer/filing/0001193125-21-362806.md","text":"https://secwatch.observer/filing/0001193125-21-362806.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000119312521362806/0001193125-21-362806-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000119312521362806/d276846d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T23:10:40.015245+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}